Navigation Links
Innovotech signs agreement for distribution of its bioFILM PA test in Israel
Date:8/12/2010

Edmonton, Alberta, July 27, 2010 Innovotech Inc. (TSX-V: IOT), a pioneer in the field of biofilm product development, has signed an exclusive distribution agreement with LevPharm Ltd of Israel to market and distribute its bioFILM PA test to hospitals and clinics within Israel.

"We are very excited to enter into this agreement with LevPharm, who recognize the significant impact the bioFILM PA test can have on improving patient care while reducing the cost burden to health care systems," said Ken Boutilier, President and CEO of Innovotech Inc. "The partnership with LevPharm illustrates their understanding of the importance of technologies for biofilm management, and further demonstrates Israel's leadership in embracing innovative products and solutions to enhance their health care system."

The current market capacity in Israel for acute infection treatment alone is estimated to be over 3,000 bioFILM PA tests per year.

bioFILM PA is the first diagnostic test to assist physicians in the selection of the most effective combination antibiotic treatment of patients with biofilm-based Pseudomonas aeruginosa infections.

Pseudomonas aeruginosa is a common bacterium responsible for many hospital acquired infections including ventilator-associated pneumonia and those found in patients with burns and wounds. It is also one of the major causes of lung infections in individuals with Cystic Fibrosis.

Over eighty percent of microbial infections in the body are caused by organisms in a biofilm state. Biofilm infections are known to be up to 4,000 times more resistant to antibiotics than the same organism in a free-floating state, which demonstrates why it is so critical to identify effective treatments early, such as through the bioFILM PA test.


'/>"/>

Contact: Ken Boutilier
ken.boutilier@innovotech.ca
780-448-0585
Innovotech Inc.
Source:Eurekalert

Page: 1

Related biology news :

1. Innovotech receives funding to advance environmentally friendly agricultural crop protection product
2. Syngenta Crop Protection Canada announces seed treatment project with Innovotech
3. Eurofins MWG Operon signs contract to supply oligonucleotides to Research Councils
4. Signs of reversal of Arctic cooling in some areas
5. Lake sturgeon have genes from parasite, signs of human STD
6. Phosphorous in sodas and processed foods accelerates signs of aging say Harvard scientists
7. Moffitt Cancer Center signs licensing agreement with Proteacel, LLC
8. Springer signs publishing agreement with ISOBM
9. Springer signs agreement with British Society of Research on Ageing
10. Copying mother natures designs
11. Plate-eating good: Université de Montréal professor designs edible tableware
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
(Date:3/31/2016)...   LegacyXChange, Inc. ... LegacyXChange is excited to release its first ... be launched online site for trading 100% guaranteed authentic ... also provide potential shareholders a sense of the value ... industry that is notorious for fraud. The video is ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: